OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Braunstein on Novel Risk Factors for Veno-Occlusive Disease Development

October 30th 2024

Marc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.

Dr Sborov on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

October 30th 2024

Douglas W. Sborov, MD, MS, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr DeAngelo on the Current Treatment Paradigm for Myelofibrosis

October 30th 2024

Daniel DeAngelo MD, PhD, discusses current treatment strategies for patients with myelofibrosis, highlighting ongoing and recently presented studies

Dr Cosgrove on T-DXd Treatment in Ovarian Cancer

October 30th 2024

Casey M. Cosgrove, MD, discusses treatment with the ADC T-DXd in patients with ovarian cancer.

Dr Badros on the Design of the AURIGA Study of Daratumumab/Lenalidomide in Newly Diagnosed Myeloma

October 30th 2024

Ashraf Z. Badros, MBCHB, discusses the design of the AURIGA trial of daratumumab plus lenalidomide in newly diagnosed myeloma following transplant.

Dr Carthon on Darolutamide Plus ADT in mHSPC

October 29th 2024

Bradley C. Carthon, MD, PhD, discusses treatment with darolutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

Dr Fisher on the Integration of Bispecific Antibodies and CAR T-cell Therapy into CRS Treatment

October 29th 2024

David C. Fisher, MD, discusses treatment with bispecific antibodies and CAR T-cell therapy, respectively, for patients with cytokine release syndrome.

Dr Tan on the Role of Nivolumab/Ipilimumab in Favorable-Risk Advanced RCC

October 29th 2024

Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma

Dr Dhakal on Notable Multiple Myeloma Trials Presented in 2024

October 29th 2024

Binod Dhakal, MD, discusses key trials presented at the 21st International Myeloma Society Annual Meeting in patients with multiple myeloma.

Dr Delforge on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Myeloma

October 29th 2024

Michel Delforge, MD, PhD, discusses the efficacy of cilta-cel in CARTITUDE-4 vs alternative approaches for lenalidomide-refractory myeloma.

Dr Feldman on the Utility of Personalized Medicine in Breast Cancer Management

October 29th 2024

Sheldon M. Feldman, MD, discusses how the use of personalized medicine has evolved in breast cancer management.

Dr Cosgrove on the Evolution of ADC Treatment in Ovarian Cancer

October 29th 2024

Casey M. Cosgrove, MD, discusses the evolution of treatment with antibody-drug conjugates for patients with ovarian cancer.

Dr Parikh on Currently Available Targeted Treatment Approaches for Mutated CRC

October 29th 2024

Aparna Parikh, MD, discusses currently available targeted therapy options for patients with colorectal cancer.

Dr Lotan on Factors Informing Treatment Selection in BCG-Unresponsive NMIBC

October 28th 2024

Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.

Dr Tan on the Selection of IO-Based Combination Regimens in Advanced RCC

October 28th 2024

Alan Tan, MD, discusses long-term data guiding the selection of immuno-oncology combination regimens in advanced renal cell carcinoma.

Dr Herrera on Nivolumab vs Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

October 28th 2024

Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.

Dr Herbst on Notable Research Avenues for Patients With Unmutated NSCLC

October 28th 2024

Roy S. Herbst, MD, PhD, discusses ongoing, planned, and future research for the management of unmutated non–small cell lung cancer.

Dr Feldman on Breast Cancer Awareness Month and Early Screening/Detection

October 28th 2024

Sheldon M. Feldman, MD, discusses the importance of Breast Cancer Awareness Month as well as timely screening and early detection.

Dr Chambers on the Importance of Patient Counseling in Ovarian Cancer

October 25th 2024

Laura J. Chambers, DO, discusses the importance of treatment counseling for patients with ovarian cancer considering PARP inhibitor therapy.

Dr Westbrook on the Evolving Understanding of Non–Clear Cell RCC Subtypes

October 25th 2024

Thomas Westbrook, MD, discusses the evolving understanding of non–clear cell renal cell carcinoma subtypes and implications for clinical practice.